These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 17059165)
1. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase. D'Cruz OJ; Uckun FM J Enzyme Inhib Med Chem; 2006 Aug; 21(4):329-50. PubMed ID: 17059165 [TBL] [Abstract][Full Text] [Related]
2. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission. D'Cruz OJ; Uckun FM Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085 [TBL] [Abstract][Full Text] [Related]
3. The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family. Chen W; Zhan P; Wu J; Li Z; Liu X Curr Pharm Des; 2012; 18(27):4165-86. PubMed ID: 22621244 [TBL] [Abstract][Full Text] [Related]
4. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors. Mao Y; Li Y; Hao M; Zhang S; Ai C J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448 [TBL] [Abstract][Full Text] [Related]
5. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. De Clercq E Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027 [TBL] [Abstract][Full Text] [Related]
6. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM Biochem Pharmacol; 2000 Nov; 60(9):1251-65. PubMed ID: 11008119 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Yu M; Fan E; Wu J; Liu X Curr Med Chem; 2011; 18(16):2376-85. PubMed ID: 21568919 [TBL] [Abstract][Full Text] [Related]
8. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors. Tabassum T; Azeem SM; Muwonge AN; Frey KM Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197 [TBL] [Abstract][Full Text] [Related]
9. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. D'Cruz OJ; Uckun FM J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862 [TBL] [Abstract][Full Text] [Related]
10. Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years. Zhuang C; Pannecouque C; De Clercq E; Chen F Acta Pharm Sin B; 2020 Jun; 10(6):961-978. PubMed ID: 32642405 [TBL] [Abstract][Full Text] [Related]
11. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163 [TBL] [Abstract][Full Text] [Related]
12. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors. Pungpo P; Hannongbua S; Wolschann P Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115 [TBL] [Abstract][Full Text] [Related]
13. HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures. Gaudio AC; Montanari CA J Comput Aided Mol Des; 2002 Apr; 16(4):287-95. PubMed ID: 12400858 [TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. De Clercq E Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775 [TBL] [Abstract][Full Text] [Related]
15. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Balzarini J Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549 [TBL] [Abstract][Full Text] [Related]
16. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. Vig R; Mao C; Venkatachalam TK; Tuel-Ahlgren L; Sudbeck EA; Uckun FM Bioorg Med Chem; 1998 Oct; 6(10):1789-97. PubMed ID: 9839009 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Barreca ML; Rao A; De Luca L; Iraci N; Monforte AM; Maga G; De Clercq E; Pannecouque C; Balzarini J; Chimirri A Bioorg Med Chem Lett; 2007 Apr; 17(7):1956-60. PubMed ID: 17276064 [TBL] [Abstract][Full Text] [Related]
18. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity. Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Mai A; Sbardella G; Artico M; Ragno R; Massa S; Novellino E; Greco G; Lavecchia A; Musiu C; La Colla M; Murgioni C; La Colla P; Loddo R J Med Chem; 2001 Aug; 44(16):2544-54. PubMed ID: 11472208 [TBL] [Abstract][Full Text] [Related]
20. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]